Assuming development is required, the following 69 results were found.
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), is the recipient of the 2021-2022 Research and Development Award presented by AMSUS, the Society of Federal Health Professionals. Zeng was honored during the AMSUS virtual annual...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
million, with the potential for up to an additional $28.5 million over 5 years, from the Biomedical Advanced Research and Development Authority (BARDA). The funding will support the further clinical development of Spero’s oral carbapenem product...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
and biological warfare agents in the field has earned a team of scientists from the U.S. Army Medical Research and Development Command’s Institute of Infectious Diseases a prestigious award from Army Futures Command. The Maj. Gen. Greene Innovation...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
than 1,300 medicines in the research pipeline, the science has never been more promising. But as industry research and development leaders warn in anew letter to the Biden Administration, the Cancer Moonshot might have to call off its mission before it...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
Cancer Center has a longstanding commitment to training the next generation of scientists and providing professional development opportunities for our faculty. Our Office of Education and Training (OET) houses educational and professional development...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
to grow and foster support for a diverse, inclusive faculty, with an emphasis on supporting faculty recruitment, career development, retention, mentorship, and leadership development. This work includes: providing training on best practices to all...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
mentoring two to four times a year. In collaboration with their faculty mentors, Scholars will develop an Individual Development Plan to help establish training goals. Scholars will participate in near-peer mentoring by Fred Hutch graduate students,...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
the most potential for successful clinical translation. NCI offers the grant as part of its Cancer Target Discovery and Development (CTD2) Network (also pronounced C-T-D-Squared). CTD2 was created to bridge the gap between genomics (the study of all the...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
from genetic sequence analyses that the Ebola virus was able to generate resistance to GS-5734. A Push for Further Development Taken together, the robust therapeutic efficacy observed in primates, the favorable drug-like properties, and the potential...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
including respiration. The brain’s natural protection — the blood-brain barrier — has long been a major obstacle to the development of effective nerve agent antidotes. Historically these countermeasures cannot cross the blood-brain barrier, and only...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
a newly funded project, part of its Open Broad Agency Announcement (Open BAA), that aims to lay the groundwork for the development of 3D printed, fully-functional human organs. There are currently more than 100,000 people in the United States who are...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
Access Non-GMO, antigen-free, generic antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated generic antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, Mayo Clinic, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.